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 ABSTRACT 
 
The key enzyme in the Campylobacter jejuni glycosylation pathway, PglB, has 
been one of the well-studied asparagine-linked oligosaccharyltransferase (OST) in 
bacterial glycoengineering area. While C. jejuni PglB performs well in transferring 
different glycans, the acceptor sites it can recognize are limited. We provided a 
thorough investigation into Desulfovibrio desulfuricans PglB (DdPglB), an OST 
sharing homology with C. jejuni PglB but having more relaxed sequon specificity. The 
sequon logo of DdPglB against XXNXT library were built through a high-throughput 
assay. Two engineered OSTs combining distinct transmembrane domain and 
periplasmic domain of PglBs from C. jejuni and D. desulfuricans was also 
investigated. And the study interestingly revealed they can lose all their glycosylation 
activities after the combination. According to the sequon logo we built and further 
verification, a notable sequon QYNST, which is a native acceptor sequon of Fc 
domain of human immunoglobulin G, was able to be glycosylated by DdPglB. 
Overall, we presented a series of sequons that can be glycosylated by DdPglB and 
further expanded the glycoengineering toolbox with more potential acceptor sites that 
were not glycosylated before. 
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Protein glycosylation, the covalent modification that attaches oligosaccharides 
to the specific protein side chain, is one of the most prevalent post-translational 
modifications found in eukaryotes. In eukaryotes, over 50% of proteins are 
glycosylated1. In addition, diverse glycans and different glycosylation sites could 
increase glycoproteins’ structure complexity and functional variety. Because of these, 
glycoproteins play important roles in various biological processes and cellular 
regulation2.  
 
Importance of glycosylation 
Researches have revealed that glycosylation can affect protein properties on 
different perspectives after modification. For instance, some of the plasma membrane 
proteins and secretory proteins require the help of glycans to fold properly3. 
Glycosylation also affects the local structure and enhances the overall stability of 
proteins4. Moreover, glycans not only promote protein folding and stability, but also 
serve as a recognition tag to influence molecular interaction in cellular processes5. In 
addition, studies show that glycosylation is important in influencing protein 






Figure 1. Multiple cellular regulation mechanisms with glycosylation involved7. 
 
 
Besides affecting protein properties, glycosylation is also critical in biological 
regulation. Specific glycans can participate in processes such as immune response to 
pathogens, adhesion, and cell-cell recognition8,9. Furthermore, intentionally modifying 
protein-associated glycans can be used to enhance the pharmacokinetic and 
therapeutic properties of proteins, such as activity, half-life, and stability in vivo10,11. 
Schematic in Figure 1 briefly summarizes that various cellular regulations all require 





Types of glycosylation 
Glycosylation can happen at several kinds of amino acid side-chains, and 
glycopeptide bonds can be arranged in distinct groups. Two main types of 
glycosylation are asparagine-linked (N-linked) glycosylation and O-linked 
glycosylation, where N-linked glycans covalently link to asparagine or arginine amide 
nitrogen, and O-linked glycans link to the hydroxyl oxygen of serine, threonine or 
other amino acid side-chains12. Other minor types of glycosylation linkage include C-
mannosyl bonds, phosphoglycosyl bonds, and glypiated linkage13.  
Among these types of glycosylation, N-linked is the most universal type. In 
this study, we focused on N-linked glycosylation to make a deeper investigation. 
 
N-linked glycosylation in eukaryotes and prokaryotes 
Although glycosylation was first found in eukaryotes, it was discovered 
prokaryotes also had native glycosylation machinery in later years. Campylobacter 
jejuni, a pathogenic gram-negative proteobacterium, was the first bacterium found 
with N-linked glycosylation pathway14. The pathway is encoded on the gene locus pgl, 
and locus pglB, which is a part of pgl, has been characterized to be translatable into a 
protein, oligosaccharyltransferases (OST). Other parts of pgl, including 
glycosyltransferase, flippase and bacillosamine, are responsible for the formation of 
glycan structure and flipping the glycan outward to the outer membrane15. Studies also 
revealed that the glycan structure of C. jejuni is the heptasaccharide GalNAc5GlcBac 
by mass spectrum (MS) and nuclear magnetic resonance (NMR)16. 
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Glycosylation systems in eukaryotes and prokaryotes share some similar 
features and mechanics17. For example, they both involve the synthesis of a lipid-
linked oligosaccharide (LLO) donor, assembling with the glycan structure, transferring 
across membrane by flippase, and finally transferring to a target protein sequon 
catalyzed by OST. The whole process can be seen in the schematic in Figure 2. 
 
 
Figure 2. Comparison of N-linked glycosylation in prokaryotes (left) and eukaryotes 
(right)18. 
 
On the other hand, there are also some notable differences between them. For 
instance, the oligosaccharides components, the lipid carrier, and the location where 
LLO assembly are different. The location of protein glycosylation pathway is also 
distinct. In eukaryotes, the modification occurs in the endoplasmic reticulum (ER) and 
Golgi, while in prokaryotes, taking C. jejuni as an example, glycan is synthesized on 
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the cytoplasmic side of the inner membrane and then flipped across the membrane and 
transferred to the substrate protein by membrane enzyme OST.  
OST is another significant difference between these two systems. In C. jejuni 
and most of the bacteria with glycosylation pathway, OST is a monomeric membrane 
protein named PglB. In contrast, in higher eukaryotes like humans, OST is constituted 
by several membrane proteins as a complex, with one of the proteins, STT3, acts as 
the key catalytic subunit19. In addition, the acceptor site sequences that OST can 
recognize are also distinct. More details about the sequences will be given in the next 
section. Interestingly, prokaryotic PglBs do share significant sequence homology with 
eukaryotic catalytic unit STT320. Thus we believe, with a deeper study into C. jejuni 
PglB, we can gain more information on eukaryotic glycosylation system. 
 
N-linked glycosylation Consensus sequon 
To successfully attach a glycan onto a target protein, it requires specific amino 
acid sequences for OSTs to recognize. For eukaryotes and archaea, glycosylation 
occurs to the amide nitrogen located in the sequence N-X-S/T, where X can be any 
amino acid but proline21.   
On the other hand, in bacteria such as C. jejuni, some initial studies found that 
N-X-S/T consensus sequence is required, but not sufficient for glycosylation22. While 
the later study extended the consensus sequon by a negatively charged amino acid in 
the -2 position in D/E-X−1-N-X+1-S/T, where X−1 and X+1 can be any amino acids 
except proline23. This means C. jejuni PglB (CjPglB) requires a more stringent motif 
compared to eukaryotic OSTs. Moreover, the sequon DQNAT was defined to be the 
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optimal sequon by an experimental way with a series of acceptor peptide substrates 
and a non-C. jejuni model protein, Im724. From these studies, we noticed that OSTs 
does play the key role in determining which protein can be glycosylated. 
 
Mechanism of oligosaccharyltransferase 
Studying the mechanism of OSTs could be the key to understand the whole 
picture of glycosylation. A previous study provided the X-ray structure of C. lari PglB 
(ClPglB) in complex with an acceptor peptide25. From this study and the structure 
shown in the top picture of Figure 3, we can conclude some critical points. First, this 
structure provided an insight into glycosylation sequon recognition. For example, the 
salt bridge between amino acid R331 of the ClPglB and aspartic acid at -2 position of 
acceptor peptide can strengthen the interaction between PglB and target protein. This 
might be the reason why CjPglB and ClPglB require D/E at -2 position to glycosylate 
protein. Another example is the van der Waals contact between the OST and threonine 
at +2 position of the peptide. This force acts as a stabilizing interaction and also 
explains why previous studies discovered glycosylation efficiency of threonine at +2 



















Figure 3. X-ray structure of C. lari PglB. PglB in complex with acceptor peptide 
DQNATF (top)25 and ternary complex structure of PglB, acceptor peptide and 
glycosidic oxygen of LLO (bottom)26. 
 
Besides, this study also proposed a possible glycosylation mechanism by the 
structure they observed. Further, several points have been concluded and stated below. 
First, the function of divalent cation M2+ was elucidated. This cation not only orients 
the acidic residues that interact with the acceptor asparagine, but also stabilizes the 
leaving LLO and glycan after successfully glycosylation. This also explained why a 
Structure of PglB with acceptor peptide (Lizak et al. Nature, 2011) 
Structure of the ternary complex (Napiórkowska et al. Scientific reports, 2018) 
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cation has been usually observed in this mechanism, and might be necessary for 
glycosylation process. Next, the periplasmic external loops in the OST structure, EL5, 
plays an important role in this reaction. EL5 was expected to be a flexible loop in the 
absence of the acceptor peptide. In the sequon binding stage, part of the EL5 is self-
organized and engages in the complex structure to stabilize the periplasmic domain of 
the OST and the acceptor sequon. After the glycan is attached, the glycopeptide is 
released by the disengagement of EL5. The later research also supported this proposed 
mechanism with ternary complex structure26.  
These pieces of evidence have all shown that specific amino acid residues on 
OSTs are crucial elements that promote glycosylation. Moreover, the transmembrane 
domain and periplasmic domain of the PglB do involve in the mechanism in different 
respects, but both play critical roles in the glycosylation process.  
 
Engineering oligosaccharyltransferase 
To increase the utilization of glycosylation, as well as broaden the knowledge 
of glycosylation mechanism, engineering OSTs can be a way with great potential, 
especially with the help of information of OSTs structure. Engineering OSTs might 
have the possibility of increasing the glycosylation efficiency of OSTs or making their 
acceptor-site specificity much broader; therefore, a number of groups have put effort 
into it. A study from DeLisa research group has successfully engineered CjPglB, and 
the mutants did have a more relaxed specificity27. The idea of engineering came from 
previous studies mentioned above, that R331 residue of ClPglB was discovered to 
form a salt bridge between OST and -2 position of acceptor peptide. Thus, this study 
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modified the residues of CjPglB which is conserved between C. jejuni and C. lari, and 
the engineered OSTs do have a wilder specificity against -2 position of the acceptor 
sequon. Furthermore, these engineered OSTs do have the ability to glycosylate wild-
type RNase A, which could not be glycosylated in the past by native CjPglB. 
Another study also focused on certain residues of CjPglB and randomly 
engineered these residues to examine if it is possible to pick up OST mutants with 
higher glycosylation efficiency28. After screening and selection by ELISA assay 
against mutagenesis library, several mutants have been picked up. The results showed 
that compared to wild-type CjPglB, some of the mutants did have better ability to 
glycosylate specific proteins, that is, the performance on glycosylation efficiency of 
the OST mutants increased significantly. 
These examples demonstrated that by engineering and modifying certain 
amino acid of OSTs, there is potential to increase their glycosylation efficiency. 
Moreover, it is also possible to create an engineered OST with relaxed sequon 
specificity, which means we will be able to glycosylate more proteins that we were not 
able to glycosylate in the past, and these new glycoproteins could further raise the 
potential for the pharmaceutical industry. 
 
Protein glycosylation in bacteria 
Instead of C. jejuni, there are more bacteria found to have similar glycosylation 
pathway. Some of these bacteria’s Pgl sequences do share some homology with C. 
jejuni, while the glycosylation efficiency and sequon specificity could be quite distinct. 
Research from DeLisa group has provided a thorough investigation into specificity for 
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the -2 sequon residue of several bacteria’s PglBs, which have native glycosylation 
pathway29. The results are shown in Figure 4. From the results, we can notice that as 
what we knew before, C. jejuni and C. lari PglB do have a narrow specificity 
(required D and E at -2 position of the sequon) but a pretty high glycosylation 
efficiency, which is 100% here.  
 
Figure 4. Glycosylation of bacteria’s PglB against scFv13-R4XQNAT variants  




In addition, Desulfovibrio desulfuricans is an interesting target here. D. 
desulfuricans PglB (DdPglB) has a quite relaxed specificity compared to all the other 
targets. Although its glycosylation efficiency is not as high as CjPglB and ClPglB, its 
performance is still very good compared to other targets, which also have relaxed 
specificities. We believe DdPglB has a great potential to glycosylate more important 
sequons that have not been glycosylated by other OSTs before. If we can properly 
modify DdPglB, it might become an engineered OST with relaxed specificity and high 
glycosylation efficiency. Therefore, we have chosen DdPglB as our main target OST 
to study in this research. 
 
Studying glycosylation in E. coli 
One of the major steps for glycoengineering is functionally transferring the C. 
jejuni glycosylation system into E. coli30. The bacterium E. coli is a good platform for 
some reasons. First, E. coli is a well-studied bacterium with the ease of production and 
manipulation. Besides, E. coli does not have glycosylation pathways; thus, we do not 
need to worry about if transferring the glycosylation system into E. coli will affect 
either the glycosylation system or E. coli. Also, E. coli is suitable for protein 
production and is a well-known bioengineering system, hence it has the potential to 
produce glycoengineering products. 
In this research, we used E. coli as our system to investigate the unknown 
sequon preferences of OSTs and to see if we could use engineered OSTs to 
glycosylate the protein of interest. 
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Research objectives  
As mentioned above, DdPglB has quite relaxed specificity; thus, we believed it 
also has the potential to glycosylate more sequons that have never been glycosylated 
before. Therefore, the first aim of this study is to investigate the sequon logo of 
DdPglB against XXNXT sequon library, where X is a randomly modified amino acid. 
Here we used Im724, a model protein which has been used to study C. jejuni 
glycosylation before, as our target protein. We also introduced a high-throughput 
screening assay developed by DeLisa group, named glycoSNAP (glycosylation of 
secreted N-linked acceptor proteins)31, to complete the sequon logo of DdPglB. 
The second objective of this research is to engineer DdPglB to see if it is 
possible to create mutants that keep relaxed specificity but have higher glycosylation 
efficiency compared to wild-type DdPglB. From the researches mentioned above, we 
noticed that the transmembrane domain and periplasmic domain of PglB might act 
functionally distinctly on stabilizing specific substrates or glycosylating certain target 
proteins. Accordingly, this research created chimeric OSTs that can combine different 
domains of CjPglB, which have high glycosylation efficiency, with DdPglB, which 
have relaxed specificity, and see the sequon preference and performance of the 
chimeric OSTs against sequons with different -2 position amino acid. 
Many important proteins have native conserved N-linked glycosylation site, 
but some of them are still left to be well-glycosylated. Therefore, the third aim of this 
project is to see if DdPglB can glycosylate certain wild-type protein’s native 
glycosylation site in our bacteria system. The investigation of DdPglB against the 
XXNXT sequon can be used here to select the most promising target, and can further 
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test the glycosylation performance of D. desulfuricans OST against this target of 
interest. The result of this study provided a potential glycoengineering target and a 






MATERIALS AND METHODS 
Overview 
To reach all the goals of this study, E. coli was used to perform all of the 
glycosylation. Three main plasmids which encoded the glycosylation pathway were 
transformed into E. coli, and the three plasmids stands for glycan production pathway, 
OST, and acceptor protein respectively. After the transformation, plasmids in E. coli 
can be induced by inducers to express the protein and execute glycosylation. Western 
blot analysis was used to detect the aglycosylated and glycosylated proteins and their 
efficiency. GlycoSNAP assay was used to screen the acceptor protein library for the 
first aim of this project. Schematic in Figure 5 briefly shows the process of this study. 
 
Figure 5. Overview of the glycosylation pathway in E. coli followed by glycoSNAP. 
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Bacterial strains and growth conditions 
The following E. coli strains were used in this study: DH5α and CLM24. 
Details are listed in Table 1 below. DH5α was used for all of the plasmid cloning, site-
directed mutagenesis, and library construction. CLM24 was used for all in vivo 
glycosylation studies. Cultures were grown in Luria-Bertani (LB) broth at 37 °C 
containing antibiotics as needed. Concentrations of the antibiotics are listed as 
following: 100 μg/ml ampicillin (Amp), 20 μg/ml chloramphenicol (Cm), 100 μg/ml 
trimethoprim (Tp), and 50 μg/ml spectinomycin (Spec). For protein expression, 
cultures were typically induced at OD600 ~0.8 by 0.04% (w/v) L-arabinose (L-ara) for 
pBAD-based expression vectors and 0.1 mM isopropyl β-D-thiogalactoside (IPTG) for 
pTrc99-based expression vectors. Induction was carried out at 30 °C for 20 h. 
Condition of protein expression was determined by a series of optimization shown in 
Figure S1, S2, and S3 in Appendix. 
 
Table 1. Strains used in this study 
Strains Relevant genotype Reference or source 
DH5α 
F– endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG purB20 φ80dlacZΔM15  
Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ– 
Laboratory stock 
CLM24 E. coli  W3110 ΔwaaL Feldman et al.32 
 
 
Plasmid construction  
All of the plasmids used in this study are listed in Table 2. Details of cloning 
and plasmid construction are described in the following page. 
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Table 2. plasmids used in this study 
Plasmids Description Reference  
pMW07-pglΔB C. jejuni pgl locus with deletion of CjPglB, Cmr Ollis et al.27 
pMAF10 Wild-type C. jejuni PglB, Tpr Feldman et al.32  
pMAF10-
CjPglBD54N E316Q C. jejuni PglB with inactivating mutation, Tp
r Ollis et al.27 
pMAF-DdOST pMAF10- derivative with C. jejuni PglB replaced by D. desulfuricans PglB, Tpr Lab stock 
pMAF-ClOST pMAF10- derivative with C. jejuni PglB replaced by C. lari PglB, Tpr Lab stock 
pMAF-CcOST pMAF10- derivative with C. jejuni PglB replaced by C. coli PglB, Tpr  Lab stock 
pMAF-
CjTMDdPDOST 
pMAF plasmid encoding transmembrane 
domain of CjPglB attached with periplasmic 




pMAF plasmid encoding transmembrane 
domain of DdPglB attached with periplasmic 




pTrc plasmid encoding signal peptide and 
model protein YebF-Im7 with engineered 




Site-directed mutagenesis of pTrc99S-YebF-
Im7DQNAT with QYNST sequon, Spr This study 
pTrc99S-YebF-
Im7XQNAT 
Series of 20 separated plasmid constructed by 
site-directed mutagenesis of pTrc99S-YebF-
Im7DQNAT with XQNAT sequon, where X are 




A mixed plasmid library constructed by site-
directed mutagenesis of pTrc99S-YebF-





Plasmids used in this study can be separated into three main groups: glycan 
production pathway, OST, and acceptor protein. For producing glycan, pMW07-
pglΔB was used. This plasmid encodes the C. jejuni pgl locus with a complete in-
frame deletion of pglB, thus serves as the whole glycosylation pathway that can 
produce C. jejuni glycan (CJG) without the functionality of OST. 
Next, pMAF10 was used to express CjPglB in this study. Plasmid pMAF10-
CjPglBD54N E316Q was a mutant with inactivation of CjPglB, and thus served as the 
negative control. pMAF-DdOST was the main target we investigated, while pMAF-
ClOST and pMAF-CcOST were also used as preliminary tests and comparison. 
Plasmids pMAF-CjTMDdPDOST and pMAF-DdTMCjPDOST were separately 
constructed by cloning transmembrane and periplasmic domains of CjPglB and 
DdPglB into pMAF backbone. PCR fragments of backbone, CjPglB, DdPglB were 
produced and then followed by Gibson assembly to complete the plasmid 
construction. Crossover sequence boundary of transmembrane and periplasmic 
domains were determined by homology comparison of the crystal structure of C. lari 
PglB25 and a proteins’ transmembrane helices prediction model33. 
Plasmid pTrc99S-YebF-Im7DQNAT was used as the optimal acceptor protein for 
CjPglB. This plasmid encodes the native yebF gene from E. coli, which can be 
translated into a signal peptide that makes E. coli transfer the target protein attached at 
its C terminus out of the outer membrane. Im7 is a model protein which has been used 
to study glycosylation of DQNAT sequon before. The engineered glycosylation 
sequence right after Im7, DQNAT, is the optimal acceptor sequon for CjPglB24. 
Plasmids pTrc99S-YebF-Im7QYNST and pTrc99S-YebF-Im7XQNAT were generated by 
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replacing DQNAT sequon with QYNST and XQNAT (X stands for 20 distinct amino 
acid) sequon by site-directed mutagenesis of the parental pTrc99S-YebF-Im7DQNAT 
plasmid. Designed primer and PCR were used and followed by Gibson assembly to 
complete the cloning. Plasmid library pTrc99S-YebF-Im7XXNXT was created by 
replacing DNA sequence GACCAaacCGCGacc (which can be translated into 
DQNAT) from pTrc99S-YebF-Im7DQNAT with NNKNNKaacNNKacc (which can be 
translated into XXNXT). Designed primer set with random NNK sequences were used 
to perform PCR and followed by T4 ligation and transformation into DH5α. Colonies 
were then screened onto plates and collected to complete the plasmid library 
construction. 
All plasmids constructed in this study were verified through DNA sequencing 
at the Cornell Biotechnology Resource Center. 
 
Protein purification  
To analyze YebF-Im7 products of in vivo glycosylation, supernatant and 
periplasmic fractions were collected and used for different parts of the experiment. For 
proteins in the supernatant, cells were pelleted after induced for 20 h and supernatant 
was collected. For periplasmic fraction, the pellet of cells was collected and 
resuspended by adding 0.4 M arginine. After reacting in 4 °C for 1 h, the supernatant 
was collected and stored as proteins in periplasmic fractions. All protein samples were 
solubilized in Laemmli sample buffer containing 5% β-mercaptoethanol (βME), and 
then boiled at 95 °C for 10 min and analyzed by western blotting. 
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Western blot assay  
Protein samples were loaded into 10% SDS-PAGE gels (BioRad) and followed 
by electrophoretic separation at 150 V for 65 min. Proteins were then transferred from 
gels onto nitrocellulose membrane and incubated for 30 min in blocking solution (5% 
non-fat milk in TBST). Membranes were washed 3 times with TBST with 10 min 
incubation between each wash. One of the membranes was then probed with anti-His 
antibodies (6xHis-polyclonal antibody, Abcam, ab137839, 1:5000 in TBS). Another 
replicate membrane was probed with hR6 (1:10000 in TBS), a serum from rabbit 
which can recognize the native C. jejuni glycan. The second membrane was then 
incubated with antirabbit-HRP secondary antibody after washing 3 times with TBST. 
Membranes were probed with antibodies at room temperature for 1 h with shaking, 
and then washed with TBST for 3 times with 10 min incubation between each wash. 
Membranes were then incubated with Western ECL substrate (BioRad). 
ChemiDocTM XRS+System was used to detect the chemiluminescent signal of the 
membranes. 
 
GlycoSNAP assay  
The target combinatorial library (which is YebF-Im7XXNXT in this study) 
transformants were plated on 150 mm LB agar plates containing 20 μg/ml Cm, 100 
μg/ml Tp as well as 50 μg/ml Spec, and incubated at 37 °C for 16-20 h. Colonies were 
then replicated onto Whatman 0.45 μm 142 mm cellulose nitrate membrane filters 
(VWR), which were overlaid on a nitrocellulose transfer membrane (Fisher 
Scientific). These membranes were placed on induction LB agar plates containing 
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20 μg/ml Cm, 100 μg/ml Tp, 50 μg/ml Spec, 0.04% (w/v) L-ara, as well as 0.1mM 
IPTG and were incubated at 30 °C for 20 h. The induction condition was determined 
by a series of optimization shown in Figure S4 in Appendix. Next day, the filters 
containing colonies were transferred onto fresh LB agar plates with the same 
antibiotics and stored at 4 °C for backup. The nitrocellulose membranes were washed 
in TBS for 10 min and then blocked with 5% (w/v) bovine serum (BSA) in TBST for 
30 min. After blocking, the membranes were incubated with lectin soybean agglutinin 
(SBA, 0.5 μg/mL in TBS) for 1 h, washed by TBS for twice with 10 min incubation 
between each wash, and then ChemiDocTM XRS+System was used to detect their 
chemiluminescent signal. Examples of probing results are presented in Figure S4 in 
Appendix. Colonies with positive signal were then picked from plates and restreaked 
on new plates with the same antibiotics for subsequent analysis. 
 
Generation of sequon logo  
After picking positive hits from GylcoSNAP of DdPglB against YebF-
Im7XXNXT library, western blot assay was used to confirm they can be glycosylated. 
These positive hits were then confirmed by DNA sequencing, and the sequon logo was  





Optimization of GlycoSNAP and growth conditions 
Before we performed glycoSNAP assay and further investigated into the 
sequon logo of DdPglB, we first optimized the whole process. The expression 
condition from previous study27 was not suitable for us here, because DdPglB shows a 
lower glycosylation level compared to CjPglB generally. We used a set of conditions 
with different amount of inducer or incubation time to find out the optimal condition, 
and parts of the testing results are shown in Figure 6. From the figure, we could notice 
that glycoSNAP signals with original condition, 0.2% L-ara plus 0.1mM IPTG, were 
very weak compared to those with our final condition, 0.04% L-ara plus 0.1mM IPTG. 
Moreover, we found out the signal strength could be increased with increasing 
incubation time. Thus, after testing with different sets of conditions, we finally 
decided to incubate the glycoSNAP at 30 °C for 20 h, and then to incubate at room 
temperature for 20 h. 
Besides the optimization of the glycoSNAP, in order to get bands with high 
quality on Western blot, we also optimized the growth conditions for DdPglB against 
YebF-Im7 protein. We tested the conditions with different amount of inducer, 
incubation time, level of OD600, or protein purification methods. All of the 
optimization blots are shown in Figure. S1, S2, and S3 in Appendix. Finally, we found 
out the optimal condition for glycosylation of DdPglB against YebF-Im7 protein, 
which was inducing the target strains with 0.04% L-ara and 0.1mM IPTG for 20 h 
when the OD600 of E. coli in LB is around 0.8. We noticed inducing at higher OD did 
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not guarantee a better glycosylation performance. In an appropriate range, a higher 
OD could lead to higher protein expression level; therefore, the signal of glycosylation 
band (g1 band) could increase, while the aglycosylation band (g0 band) could also 
increase. Overall, this could cause a slight decrease in glycosylation efficiency. 
 
 
Figure 6. Optimization of glycoSNAP at different conditions. GlycoSNAP of DdPglB 
against YebF-Im7AQNAT was performed with different amount of inducer, L-ara or 
IPTG, at 30 °C for 20 h, and then followed by incubating at room temperature for 20 
h. All the blots were incubated in the same LB agar plate with appropriate antibiotics 
and probed with the lectin SBA. The negative control reaction (-) was performed using 
the inactivated OST mutant CjPglBD54N E316Q against YebF-Im7DQNAT. Red arrow 
indicates the optimal condition we used in this project. 
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Sequon logos of DdPglB  
To fully investigate the acceptor sequon specificity of D. desulfuricans PglB, 
an acceptor protein library YebF-Im7XXNXT was built. Asparagine at the central 
position was fixed for N-linked glycosylation, and threonine at +2 position was also 
fixed because it is one of the required residues for eukaryotic OSTs. X at -2, -1 and +1 
positions of the sequon represents a randomly generated amino acid. DdPglB was 
tested against this protein library in E. coli, and screened by glycoSNAP assay. 72 
potential hits from the glycoSNAP assay were picked up, and further verified by 
Western blot. 33 hits among them were positively glycosylated. These glycosylated 
hits were then examined by DNA sequencing to verify the sequon. The Western blot 
and sequencing results are shown in Figure 7.  
The negative control reaction (-) was performed using the inactivated OST 
mutant CjPglBD54N E316Q against YebF-Im7DQNAT, and positive control reaction (+) was 
performed by DdPglB against YebF-Im7AQNAT, one of sequons that can be 
glycosylated with the highest efficiency for DdPglB in the previous study29. These 
controls were used to demonstrate the position of the aglycosylated and glycosylated 
bands in Western blot. The same control reactions were used in all of the following 
Western blot results in this study. 
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Figure 7. Positive hits of DdPglB against YebF-Im7XXNXT library. Immunoblot 
analysis of periplasmic fractions from CLM24 cells complemented with DdPglB, and 
co-expressing the biosynthetic pathway for the C. jejuni glycan and protein YebF-
Im7XXNXT (X indicate random amino acids). Samples were picked from positive hits of 
the glycoSNAP assay. Sequencing results are shown on top of the blot. Molecular 
weight (MW) markers are indicated on the left. The g0 and g1 on the right indicate 
aglycosylated and glycosylated forms of the target protein, respectively. Black boxes 
denote the samples in the same blot, while gray dotted lines denote the samples are 
nonadjacent.  
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 From the results in Figure 7, we observed most of the samples’ glycosylation 
efficiencies are around 50% or lower. The positive control DdPglB against sequon 
AQNAT had an efficiency of 30%. One of the noticeable sequons was SHNAT, which 
had the highest glycosylation efficiency of 70% among this panel. 
After the thorough screening and Western blotting verification, we collected 
several positive hits of sequon which can be glycosylated by DdPglB. Next, the 
sequence logo of DdPglB against XXNXT sequon was generated by using Weblogo 
334. The result is shown in Figure 8. The result indicated DdPglB did not have strong 
preferences at -2 position of the acceptor motif compared to CjPglB, which required 
D/E at -2 position. A preference of S/A/G at +1 position was also observed in this 
result. Overall, from this sequence logo, DdPglB did have a relaxed acceptor-site 
specificity. 
 
Figure 8. Sequence logo of DdPglB against YebF-Im7XXNXT library. Sequence logo 
showing experimentally determined acceptor-sequon specificity of DdPglB against 
YebF-Im7XXNXT library using glycoSNAP screening assay. 
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Chimeric C. jejuni-D. desulfuricans OST  
After the investigation of relaxed sequon specificity of DdPglB, engineered 
OSTs were then constructed and tested for substrate specificity. Engineered OSTs 
were constructed by standard cloning technic which combined transmembrane domain 
and periplasmic domain of two different OSTs, CjPglB and DdPglB. DdPglB has been 
verified for its relaxed specificity while CjPglB was chosen for its high glycosylation 
efficiency. Engineered chimeric OSTs that combined transmembrane domain of 
CjPglB (amino acids numbered 1-429 of CjPglB) with periplasmic domain of DdPglB 
(amino acids numbered 469-729 if DdPglB), CjTMDdPDOST, and a reverse mutant 
DdTMCjPDOST (combined amino acids numbered 1-468 of DdPglB and 430-714 of 
CjPglB) were then tested against the acceptor motif XQNAT where -2 position was 
varied to include all 20 amino acids. The same C. jejuni glycan production pathway 
and acceptor protein YebF-Im7 were used in this experiment. Results are presented 
below in Figure 9. 
From the results, we noticed that while the proteins were expressed well in the 
immunoblot analysis, both engineered CjTMDdPDOST and DdTMCjPDOST did not have 
the ability to glycosylate any of the sequons with 20 amino acids at -2 position. 
Compared to the previous study in Figure 4, we noticed their original ability of 






Figure 9. Specificities of chimeric OSTs combined CjPglB and DdPglB. Immunoblot 
of acceptor protein YebF-Im7XQNAT, where X is one of the 20 amino acids indicated 
on top, co-expressed with the biosynthetic pathway for the C. jejuni glycan (CJG) and 
engineered (a) CjTMDdPDOST and (b) DdTMCjPDOST. Molecular weight (MW) 
markers are indicated on the left. The g0 and g1 on the right indicate aglycosylated 
and glycosylated forms of the target protein, respectively. Black boxes denote the 




Glycosylation of native human IgG1 acceptor sequon by DdPglB  
From the sequon logo result of DdPglB, we noticed there was an interesting 
potential sequon that can be glycosylated by DdPglB, QYNST, which is a single 
conserved glycosylation site of the human immunoglobulin G (IgG) on its Fc domain. 
Therefore, we performed an experiment to verify if DdPglB can glycosylate this 
sequon in our system. The plasmid containing acceptor protein YebF-Im7XQNAT was 
then constructed and co-expressed with DdPglB and C. jejuni glycan pathway. The 
result is shown in Figure 10, which indicates sequon QYNST can be successfully 










Figure 10. Glycosylation of DdPglB against YebF-Im7QYNST. Immunoblot of protein 
YebF-Im7QYNST co-expressed with the biosynthetic pathway for the C. jejuni glycan 
(CJG) and DdPglB. Molecular weight (MW) markers are indicated on the left. The g0 
and g1 on the right indicate aglycosylated and glycosylated forms of the protein 





DdPglB has been one of the OSTs with relaxed sequon specificity at the -2 
position relative to the central asparagine. Here, we performed a more thorough 
investigation by the glycoSNAP screening against XXNXT sequon library, and the 
screening results indicated the acceptor-site specificity of DdPglB was certainly quite 
relaxed, especially at the -2 and -1 position, while DdPglB might have a preference for 
S/A/G amino acids at +1 position. The verification of the positive hits also provided a 
series of sequon that can be glycosylated by DdPglB and testified their performance 
on glycosylation efficiency. These results could serve as a glycoengineering toolbox 
and database for glycosylating various native protein acceptor sequons in the future. 
One noticeable result was the sequon SHNAT can be glycosylated by DdPglB with 
67% glycosylation efficiency, which was the highest efficiency among all the 
literature reported efficiencies. Thus, here we also provided the sequon SHNAT as a 
new optimal acceptor sequon that was most suitable for glycosylation of DdPglB so 
far.  
The single crossover engineered chimeric OSTs CjTMDdPDOST and 
DdTMCjPDOST were also constructed and investigated in this study. Transmembrane 
domain and periplasmic domains might have distinct abilities to support the reaction 
of OSTs, such as stabilizing the acceptor sequon or glycan complex by van der Waals 
contact, salt bridge, etc25. However, our results interestingly revealed that these two 
constructs could lose their ability to glycosylate the acceptor sequon that their original 
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full-length PglB were able to glycosylate. These indicated that some of the amino 
acids around the crossover point that we replaced in this experiment could play an 
important role in affecting the activity of these enzymes and their glycosylation 
ability. In the future, a series of single crossover chimeric OSTs could be constructed 
and screened through glycoSNAP to investigate what section of PglBs is the key part 
that affects glycosylation activity. This study and the future plan might provide an 
insight into the glycosylation mechanism of OSTs.  
In this study, we also confirmed that sequon QYNST with the model protein 
Im7 can be glycosylated by DdPglB in E coli. QYNST is the native conserved 
glycosylation site at N297 of the Fc domain of human IgG. Therefore, successful 
glycosylation of this sequon has great significance here. So far, there are no other 
bacteria OSTs proved to have the ability to glycosylate sequon QYNST with 
efficiency higher than that in this study, which is 40%. In the future, we can perform a 
further investigation to check if DdPglB can also glycosylate the native Fc domain of 
human IgG, which might have the potential to be expressed as the glycoprotein with 





This study provided a thorough investigation into the acceptor-site preference 
of DdPglB, and demonstrated DdPglB had a quite relaxed sequon specificity by 
building the sequence logo. A series of sequons which can be glycosylated by DdPglB 
was also presented, as well as their glycosylation performance. Thereby, the database 
of potential acceptor-sequon was expanded.  
In addition, the engineered chimeric OSTs CjTMDdPDOST and DdTMCjPDOST 
were constructed here. Their glycosylation activity was eliminated after the 
combination of transmembrane and periplasmic domains from the two different 
bacterial PglBs. This indicated amino acids around the crossover section might serve a 
key role in the functionality of these OSTs.   
Finally, sequence logo of DdPglB indicated QYNST, a native acceptor sequon 
of Fc domain of human IgG, could be potentially glycosylated by DdPglB. The result 
was also verified by immunoblot analysis and proved that DdPglB was able to 
glycosylate this sequon attached on C-terminus of the model protein YebF-Im7QYNST 
with an efficiency of 40%. Our research showed that DdPglB had the potential for 
glycosylating the native acceptor-site of human IgG.  
In conclusion, we presented a list of sequons that can be glycosylated by 





Supplementary information   
 
Figure S1. Expression optimization of R4AQNAT and Im7AQNAT at different conditions.  
 
Figure S2. Expression optimization of Im7QSNST at different conditions. 
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Figure S3. Expression optimization of Im7AQNAT at different conditions. (Red arrow 
indicates the optimize condition) 
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